JNJJohnson & Johnson
Is it safe?
Solid, nothing alarming. No accounting flags, quality moderate.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$67.8M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Relatively steady, low volatility. Worst drawdown -27% · now 6% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 28, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can JNJ take a bad year?
The deepest fall in JNJ's price history on file is −27%; it is 6.0% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand
- Debt / equity
- 0.58×
Debt / equity
- Annualised volatility
- 19%
Annualised volatility · about as steady as the market itself
- Worst drawdown on file
- −27%
Worst drawdown on file · −6.0% today
Details›
- Total debtQ2 2026
- $49.0B
- Cash and short-term investments
- $20.8B
- Net debt
- $28.3B
- Debt / equity
- 0.58×
- Annualised volatilitytwo years of daily moves
- 19%
- Worst drawdown on file
- −27%
- Below its 52-week high
- 6.0%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, General
The closest names by size in the same industry